MARKET

PTCT

PTCT

Ptc Therapeutics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

30.34
-1.02
-3.25%
Opening 11:36 05/25 EDT
OPEN
31.09
PREV CLOSE
31.36
HIGH
31.60
LOW
30.30
VOLUME
141.51K
TURNOVER
3.12M
52 WEEK HIGH
45.80
52 WEEK LOW
30.03
MARKET CAP
2.16B
P/E (TTM)
-4.1107
1D
5D
1M
3M
1Y
5Y
Raymond James Says PTC Therapeutics' CHMP Backing Is 'Under Exceptional Circumstances' What's Next
Benzinga · 20h ago
Europe's CHMP Backs Approval Of PTC Therapeutics' Gene Therapy In Rare Neurometabolic Disorder
Benzinga · 4d ago
BRIEF-PTC Therapeutics Receives Positive CHMP Opinion For Upstaza For AADC Deficiency Treatment
reuters.com · 5d ago
PTC Therapeutics gene therapy Upstaza gets EMA panel nod for ultra-rare genetic disorder
A committee of the European Medicines Agency (EMA) recommended the approval of PTC Therapeutics' (NASDAQ:PTCT) one time gene therapy Upstaza to treat aromatic L-amino acid decarboxylase (AADC) deficiency in children and adults.
Seekingalpha · 5d ago
PTC Therapeutics Reports Positive European Medicines Agency Committee For Medicinal Products For Human Use Opinion For Upstaza For Treatment Of Aromatic L-Amino Acid Decarboxylase Deficiency
– First ever gene therapy directly administered into the brain – – Recommended for regulatory approval by EMA – – Results demonstrated sustained improvements in motor and cognitive
Benzinga · 5d ago
PTC Therapeutics Receives Positive CHMP Opinion for Upstaza™ for the Treatment of AADC Deficiency
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Upstaza™ (eladocagene exuparvovec; PTC-AADC) received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). Once ratified by the ...
PR Newswire · 5d ago
PTC Therapeutics Receives Positive EMA Panel Opinion for Upstaza to Treat Rare Genetic Disorder
MT Newswires · 5d ago
PTC Therapeutics's Return On Capital Employed Overview
According to data from Benzinga Pro, during Q1, PTC Therapeutics's (NASDAQ:PTCT) reported sales totaled $148.74 million. Despite a 11.54% increase in earnings, the company posted a loss of $126.73 million.
Benzinga · 05/12 14:16
More
No Data
Learn about the latest financial forecast of PTCT. Analyze the recent business situations of Ptc Therapeutics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 11 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

9.09%Strong Buy
36.36%Buy
45.45%Hold
9.09%Under-perform
0.00%Sell
Analyst Price Target
The average PTCT stock price target is 47.11 with a high estimate of 63.00 and a low estimate of 32.00.
High63.00
Average47.11
Low32.00
Current 30.34
EPS
Actual
Estimate
-1.62-1.22-0.81-0.41
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 282
Institutional Holdings: 77.27M
% Owned: 108.31%
Shares Outstanding: 71.34M
TypeInstitutionsShares
Increased
60
4.90M
New
26
656.22K
Decreased
55
5.92M
Sold Out
16
544.77K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.32%
Pharmaceuticals & Medical Research
-0.19%
Key Executives
Non-Executive Chairman/Independent Director
Michael Schmertzler
Chief Executive Officer/Director
Stuart Peltz
Chief Financial Officer
Emily Hill
Chief Operating Officer/Chief Technology Officer
Neil Almstead
Chief Operating Officer
Matthew Klein
Executive Vice President
Mark Boulding
Senior Vice President/Chief Accounting Officer
Christine Utter
Other
Eric Pauwels
Independent Director
Allan Jacobson
Independent Director
Stephanie Okey
Independent Director
Emma Reeve
Independent Director
Mary Smith
Independent Director
David Southwell
Independent Director
Glenn Steele
Independent Director
Dawn Svoronos
Independent Director
Jerome Zeldis
No Data
No Data
About PTCT
PTC Therapeutics, Inc. is a science-driven global biopharmaceutical company. The Company is focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The Company's portfolio pipeline includes several commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focused on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology. The Company has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD). It has a pipeline of gene therapy product candidates for rare monogenic diseases that affect the central nervous system (CNS), including PTC-AADC for the treatment of Aromatic L-Amino Acid Decarboxylase (AADC).

Webull offers kinds of PTC Therapeutics, Inc. stock information, including NASDAQ:PTCT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PTCT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PTCT stock methods without spending real money on the virtual paper trading platform.